» Articles » PMID: 29455730

Enhancement of Oral Bioavailability and Immune Response of Ginsenoside Rh2 by Co-administration with Piperine

Overview
Journal Chin J Nat Med
Publisher Science Press
Date 2018 Feb 20
PMID 29455730
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Ginsenoside Rh2 (Rh2) is one of the major bioactive ginsenosides in Panax ginseng. However, the oral bioavailability of Rh2 is low, with P-glycoprotein (P-gp) and CYP3A4 being reported to be the main factors. The purpose of the present study was to determine the enhancing effect of piperine on the oral bioavailability as well as bioactivity of Rh2. The inhibitory effect of piperine on P-gp and CYP3A4 was determined using a Caco-2 monolayer model and a recombinant CYP3A4 metabolic system, respectively. The pharmacokinetics of oral Rh2 (10 mg·kg) administered alone or in combination with piperine (10 and 20 mg·kg) was performed in rats. The immune boosting effect of Rh2 was assessed in rats by measuring IL-12 level after treated by Rh2 alone or co-administered with piperine. The results indicated that piperine significantly increased the permeability of Rh2 and inhibited the metabolism of Rh2. The pharmacokinetic study results showed that the AUC of Rh2 was significantly increased in combination with piperine at high dose (20 mg·kg) when compared to the control group, with relative bioavailability of 196.8%. The increase of Rh2 exposure led to increased serum levels of IL-12. In conclusion, piperine may be used as a bioenhancer to improve pharmacological effect of Rh2 when given orally.

Citing Articles

A scientifically validated combination of garcinol, curcuminoids, and piperine for mild to moderate nonalcoholic steatohepatitis patients-results from a randomized, double-blind, placebo-controlled study.

Majeed M, Nagabhushanam K, Noureddin M, Paulose S, Barik C, Saklecha S Front Nutr. 2024; 10:1201186.

PMID: 38170037 PMC: 10760641. DOI: 10.3389/fnut.2023.1201186.


Methods on improvements of the poor oral bioavailability of ginsenosides: Pre-processing, structural modification, drug combination, and micro- or nano- delivery system.

Hu Q, Hong H, Zhang Z, Feng H, Luo T, Li J J Ginseng Res. 2023; 47(6):694-705.

PMID: 38107396 PMC: 10721471. DOI: 10.1016/j.jgr.2023.07.005.


Phytochemicals Target Multiple Metabolic Pathways in Cancer.

Shuvalov O, Kirdeeva Y, Daks A, Fedorova O, Parfenyev S, Simon H Antioxidants (Basel). 2023; 12(11).

PMID: 38001865 PMC: 10669507. DOI: 10.3390/antiox12112012.


Pharmacokinetics and pharmacodynamics of Rh2 and aPPD ginsenosides in prostate cancer: a drug interaction perspective.

Ben-Eltriki M, Shankar G, Guns E, Deb S Cancer Chemother Pharmacol. 2023; 92(6):419-437.

PMID: 37709921 DOI: 10.1007/s00280-023-04583-y.


The preventive role of the red gingeng ginsenoside Rg3 in the treatment of lung tumorigenesis induced by benzo(a)pyrene.

Xiong J, Yuan H, Fei S, Yang S, You M, Liu L Sci Rep. 2023; 13(1):4528.

PMID: 36941308 PMC: 10027881. DOI: 10.1038/s41598-023-31710-9.